Abstract

Objectives: We aimed to investigate the expression levels and interaction between E2F-1 and Akt1 in triple-negative breast cancer (TNBC) cells, and whether cis-diamminedichloroplatinum(II) (cisplatin) could influence such an interaction. Methods: A batch of MDA-MB-321 breast cancer cells were treated with increasing concentrations of cisplatin (2.5–40 μM) for 24 hours. Additional cells from the same source were used for control experiments. Cisplatin-induced apoptosis was confirmed biochemically using cleaved polymerase and flow cytometry analysis, and morphologically using hematoxylin and eosin staining, Hoechst staining, and scanning electron microscopy. Caspase-3 cleavage, an indicator of apoptotic induction, was measured by immunofluorescence. A western blot test was used to investigate the effects of cisplatin on E2F-1 and Akt1 expressions, while their co-localization and interaction were detected using immunofluorescence and immunoprecipitation, respectively. Results: A western blot analysis revealed an increase in E2F-1 and a decrease in Akt1 expression with increasing concentration of cisplatin, compared to untreated cells. Merged E2F-1 and Akt1 immunosignals observed by immunofluorescence demonstrated that cisplatin-treated cells exhibited co-localization of immunosignals in clusters and with increased intensity in the cytoplasm. Immunoprecipitation and western blot analysis results further confirmed the association between E2F-1 and Akt1, indicating a potential interaction between the two proteins in MDA-MB-231 cells. Conclusions: Our findings suggest a potential interaction between E2F-1 and Akt1, which in turn could be the precursor for the cisplatin-induced apoptosis in TNBC cells. Further studies are needed to determine whether this interaction occurs directly or via an intermediate protein.

Keywords

Subject

Publication details

DOI
10.5001/omj.2025.41
Journal
Oman Medical Journal
Publisher
Oman Medical Specialty Board
Open access
Gold open access

Cite this article

APA 7

Al-Jaaidi, S., Al-Dhahli, B., Al Sibani, A., Al Harthi, T., Al Ghafri, H., & Al-Bahlani, S. (2025). E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells. Oman Medical Journal. https://doi.org/10.5001/omj.2025.41

MLA 9

Al-Jaaidi, Samiya, et al. "E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells." Oman Medical Journal, 2025. https://doi.org/10.5001/omj.2025.41.

Chicago (author–date)

Al-Jaaidi, Samiya, Buthaina Al-Dhahli, Asma Al Sibani, Thraia Al Harthi, Hajar Al Ghafri, and Shadia Al-Bahlani. 2025. "E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells." Oman Medical Journal. https://doi.org/10.5001/omj.2025.41.

Harvard

Al-Jaaidi, S., Al-Dhahli, B., Al Sibani, A., Al Harthi, T., Al Ghafri, H. and Al-Bahlani, S. (2025) 'E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells', Oman Medical Journal. doi:10.5001/omj.2025.41.

Vancouver

Al-Jaaidi S, Al-Dhahli B, Al Sibani A, Al Harthi T, Al Ghafri H, Al-Bahlani S. E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells. Oman Medical Journal. 2025. doi:10.5001/omj.2025.41

IEEE

S. Al-Jaaidi, B. Al-Dhahli, A. Al Sibani, T. Al Harthi, H. Al Ghafri, and S. Al-Bahlani, "E2F-1–Akt1 Interaction as Precursor to Cisplatin-induced Apoptosis in Triple-negative Breast Cancer Cells," Oman Medical Journal, 2025, doi: 10.5001/omj.2025.41.